205 related articles for article (PubMed ID: 26686201)
1. A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041).
Chiu JW; Hotte SJ; Kollmannsberger CK; Renouf DJ; Cescon DW; Hedley D; Chow S; Moscow J; Chen Z; Perry M; Diaz-Padilla I; Tan D; Hirte H; McWhirter E; Chen H; Siu LL; Bedard PL
Invest New Drugs; 2016 Feb; 34(1):104-11. PubMed ID: 26686201
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.
Kyriakopoulos CE; Braden AM; Kolesar JM; Eickhoff JC; Bailey HH; Heideman J; Liu G; Wisinski KB
Invest New Drugs; 2017 Jun; 35(3):290-297. PubMed ID: 28004284
[TBL] [Abstract][Full Text] [Related]
3. Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.
Amin M; Gao F; Terrero G; Picus J; Wang-Gillam A; Suresh R; Ma C; Tan B; Baggstrom M; Naughton MJ; Trull L; Belanger S; Fracasso PM; Lockhart AC
Am J Clin Oncol; 2021 Sep; 44(9):443-448. PubMed ID: 34310349
[TBL] [Abstract][Full Text] [Related]
4. A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
Infante JR; Cohen RB; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; LoRusso PM
Invest New Drugs; 2017 Oct; 35(5):576-588. PubMed ID: 28424891
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies.
Trivedi ND; Armstrong S; Wang H; Hartley M; Deeken J; Ruth He A; Subramaniam D; Melville H; Albanese C; Marshall JL; Hwang J; Pishvaian MJ
Cancer Med; 2021 Mar; 10(6):1944-1954. PubMed ID: 33638305
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors.
Piatek CI; Raja GL; Ji L; Gitlitz BJ; Dorff TB; Quinn DI; Hu J; El-Khoueiry AB; Pham HQ; Roman L; Garcia AA
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1227-34. PubMed ID: 25374407
[TBL] [Abstract][Full Text] [Related]
7. A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery.
Vergote I; Oaknin A; Baurain JF; Ananda S; Wong S; Su X; Wu B; Zhong Z; Warner D; Casado A
Eur J Cancer; 2014 Sep; 50(14):2408-16. PubMed ID: 25037684
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
Gandhi L; Bahleda R; Tolaney SM; Kwak EL; Cleary JM; Pandya SS; Hollebecque A; Abbas R; Ananthakrishnan R; Berkenblit A; Krygowski M; Liang Y; Turnbull KW; Shapiro GI; Soria JC
J Clin Oncol; 2014 Jan; 32(2):68-75. PubMed ID: 24323026
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.
Khawaja MR; Nick AM; Madhusudanannair V; Fu S; Hong D; McQuinn LM; Ng CS; Piha-Paul SA; Janku F; Subbiah V; Tsimberidou A; Karp D; Meric-Bernstam F; Lu KH; Naing A
Cancer Chemother Pharmacol; 2016 May; 77(5):973-7. PubMed ID: 27014780
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors.
Park H; Williams K; Trikalinos NA; Larson S; Tan B; Waqar S; Suresh R; Morgensztern D; Van Tine BA; Govindan R; Luo J; Lockhart AC; Wang-Gillam A
Cancer Chemother Pharmacol; 2021 Mar; 87(3):337-347. PubMed ID: 33159216
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours.
Hollebecque A; Bahleda R; Faivre L; Adam J; Poinsignon V; Paci A; Gomez-Roca C; Thery JC; Le Deley MC; Varga A; Gazzah A; Ileana E; Gharib M; Angevin E; Malekzadeh K; Massard C; Soria JC; Spano JP
Eur J Cancer; 2017 Aug; 81():81-89. PubMed ID: 28618305
[TBL] [Abstract][Full Text] [Related]
12. A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report.
Fouladi M; Perentesis JP; Wagner LM; Vinks AA; Reid JM; Ahern C; Thomas G; Mercer CA; Krueger DA; Houghton PJ; Doyle LA; Chen H; Weigel B; Blaney SM
Clin Cancer Res; 2015 Apr; 21(7):1558-65. PubMed ID: 25467181
[TBL] [Abstract][Full Text] [Related]
13. A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.
Diaz-Padilla I; Hirte H; Oza AM; Clarke BA; Cohen B; Reedjik M; Zhang T; Kamel-Reid S; Ivy SP; Hotte SJ; Razak AA; Chen EX; Brana I; Wizemann M; Wang L; Siu LL; Bedard PL
Invest New Drugs; 2013 Oct; 31(5):1182-91. PubMed ID: 23860641
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors.
Bryce AH; Rao R; Sarkaria J; Reid JM; Qi Y; Qin R; James CD; Jenkins RB; Boni J; Erlichman C; Haluska P
Invest New Drugs; 2012 Oct; 30(5):1934-41. PubMed ID: 21881915
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.
Mita M; Fu S; Piha-Paul SA; Janku F; Mita A; Natale R; Guo W; Zhao C; Kurzrock R; Naing A
Invest New Drugs; 2017 Oct; 35(5):616-626. PubMed ID: 28194539
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors.
Diamond JR; Wu B; Agarwal N; Bowles DW; Lam ET; Werner TL; Rasmussen E; Gamelin E; Soto F; Friberg G; Sun YN; Sharma S
Invest New Drugs; 2015 Jun; 33(3):691-9. PubMed ID: 25895965
[TBL] [Abstract][Full Text] [Related]
17. Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer.
Kaufman PA; Wildiers H; Freyer G; Kemeny M; Gonçalves A; Jerusalem G; Stopeck A; Vrindavanam N; Dalenc F; Nanayakkara N; Wu B; Pickett CA
Clin Breast Cancer; 2019 Feb; 19(1):47-57. PubMed ID: 30420181
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors.
Semrad TJ; Eddings C; Dutia MP; Christensen S; Lara PN
Anticancer Drugs; 2013 Jul; 24(6):636-40. PubMed ID: 23698253
[TBL] [Abstract][Full Text] [Related]
19. A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours.
Hong DS; Kurzrock R; Mulay M; Rasmussen E; Wu BM; Bass MB; Zhong ZD; Friberg G; Rosen LS
Oncotarget; 2014 Nov; 5(22):11154-67. PubMed ID: 25525888
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors.
Fury MG; Sherman E; Haque S; Korte S; Lisa D; Shen R; Wu N; Pfister D
Cancer Chemother Pharmacol; 2012 Mar; 69(3):591-8. PubMed ID: 21913034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
